Today
+0.59%
5 Days
+2.50%
1 Month
+11.47%
6 Months
-2.49%
Year to Date
-1.68%
1 Year
+2.84%
• Capital rotated from defensive healthcare stocks into higher-beta growth sectors in June. • Medtronic’s share price declined following disappointing fiscal 2027 forward-looking guidance. • FTSE Russell index reconstitution and ex-dividend adjustments increased stock trading volatility.
• Abbott's share price rose due to diabetes and oncology news. • CE Mark for dual glucose-ketone sensing technology approved. • Strong earnings, revenue, and maintained full-year guidance.
• Medtronic reported strong Q4 FY26 revenue exceeding expectations. • Company announced dividend increase and optimistic FY27 outlook. • Strategic moves include FDA filings, acquisitions, and investments.
• Medtronic's share price declined due to negative analyst sentiment. • Cybersecurity incident disclosure contributed to investor concerns and uncertainty. • Stock reached a 52-week low, signaling lack of investor confidence.
• HCA Healthcare shares rose on analyst sentiment and company guidance. • Institutional investors increased their positions in HCA Healthcare. • Strong 2026 EBITDA guidance surpasses investor expectations.
• UnitedHealth faces intensified regulatory scrutiny and legal investigations. • Change Healthcare cyberattack cost estimates increased significantly. • Analyst sentiment is mixed, with price target trims and downgrades.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.49% |
| BlackRock Institutional Trust Company, N.A. | 5.22% |
| State Street Investment Management (US) | 4.80% |
| JP Morgan Asset Management | 3.16% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.99% |
| Investment Advisor/Hedge Fund | 29.82% |
| Research Firm | 3.63% |
| Pension Fund | 2.17% |
Related Instruments
Popular Instruments